News

The patient recruitment has been started following the Argentinean approval which permits the company to recruit around eight patients with type 1 diabetes and severe hypoglycaemia. In the

In May this year Sanofi had signed a $613m licensing pact with Glenmark Pharmaceuticals Limited India (GPL) subsidiary Glenmark Pharmaceuticals SA (GPSA) to develop and commercialize a monoclonal

According to animal studies, amifostine protects against genomic instability and associated long term genomic damages resulting from radiation exposure, such as from CT scans and other diagnostic radiology

The company’s sBLA is supported by the results of a Phase 3 Study (‘147) investigating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. The results of

RP101, a first-in-class small molecule addressing chemo resistance in human cancers with initial focus on pancreatic carcinoma, is to be given in a combination with chemotherapy. Recently, RP101

The agreement allows the commercial partner to continue its research cooperation with Dyadic Netherlands, the R&D subsidiary of Dyadic. Additionally, it will use Dyadic’s patented and proprietary C1

Hsp90 is a member of the heat shock protein family which assists in protein folding, cell signaling, and tumor repression and is a novel target for oncology and

The FDA’s decision follows a Pre-Approval Inspection (PAI) which was done in April 2011 by the US regulators. The company expects to do the filling and packaging of

Teva intends to team up with another two Israeli clinical centers for conducting the study (immunotherapy Multikine anti tumor treatments (IT-MATTERS)), which is already ongoing at several clinical